(MGNX) MacroGenics - Overview
Stock: Lorigerlimab, MGC026, MGC028, MGC030
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.5% |
| Relative Tail Risk | -14.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.11 |
| Alpha | -62.22 |
| Character TTM | |
|---|---|
| Beta | 1.634 |
| Beta Downside | 0.911 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.06% |
| CAGR/Max DD | -0.33 |
Description: MGNX MacroGenics January 20, 2026
MacroGenics, Inc. (NASDAQ:MGNX) is a clinical-stage biopharma focused on antibody-based oncology therapeutics in the United States. Its pipeline features lorigerlimab-a bispecific DART that simultaneously blocks PD-1 and CTLA-4-currently in Phase 2 trials for metastatic castration-resistant prostate cancer (mCRPC) and in Phase 2 for docetaxel-refractory ovarian and clear-cell gynecologic cancers after completing Phase 1. The company also advances several antibody-drug conjugates (ADCs): MGC026 (B7-H3-targeted with a novel topoisomerase I inhibitor payload), MGC028 (ADAM9-targeted with a similar TOP1i payload) in Phase 1, and MGC030 (preclinical). In addition, MacroGenics is pursuing next-generation T-cell engager programs and maintains collaborations with TerSera Therapeutics, Incyte, and Gilead Sciences. The firm was incorporated in 2000 and is headquartered in Rockville, Maryland.
Key quantitative signals (as of the most recent 10-Q filing, Q3 2024) include: • Cash and cash equivalents of roughly $120 million, providing runway through 2025 under current burn rates (~$45 million per year). • R&D expense grew 18 % YoY to $68 million, reflecting accelerated Phase 2 enrollment for lorigerlimab. • The immuno-oncology market is projected to expand at ~10 % CAGR through 2030, offering a favorable macro backdrop for checkpoint-inhibitor combos. • MacroGenics’ partnership with Gilead includes a $30 million upfront payment and tiered milestones that could materially de-risk the lorigerlimab program if Phase 2 endpoints are met.
Given the high-risk, high-reward nature of early-stage oncology assets, a disciplined valuation framework is essential; you may find it useful to explore the ValueRay platform’s detailed financial models for MGNX to assess upside scenarios and downside protection.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -75.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.61 > 0.02 and ΔFCF/TA -37.52 > 1.0 |
| NWC/Revenue: 148.9% < 20% (prev 115.3%; Δ 33.65% < -1%) |
| CFO/TA -0.60 > 3% & CFO -162.5m > Net Income -75.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.3m) vs 12m ago 0.66% < -2% |
| Gross Margin: 73.67% > 18% (prev 0.33%; Δ 7334 % > 0.5%) |
| Asset Turnover: 47.08% > 50% (prev 53.43%; Δ -6.35% > 0%) |
| Interest Coverage Ratio: -16.58 > 6 (EBITDA TTM -63.1m / Interest Expense TTM 4.26m) |
Altman Z'' -15.00
| A: 0.69 (Total Current Assets 232.1m - Total Current Liabilities 44.5m) / Total Assets 270.8m |
| B: -4.54 (Retained Earnings -1.23b / Total Assets 270.8m) |
| C: -0.26 (EBIT TTM -70.6m / Avg Total Assets 267.6m) |
| D: -6.03 (Book Value of Equity -1.23b / Total Liabilities 203.8m) |
| Altman-Z'' Score: -18.38 = D |
Beneish M 1.00
| DSRI: 8.87 (Receivables 69.2m/8.75m, Revenue 126.0m/141.3m) |
| GMI: 0.45 (GM 73.67% / 32.88%) |
| AQI: 1.15 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.89 (Revenue 126.0m / 141.3m) |
| TATA: 0.32 (NI -75.9m - CFO -162.5m) / TA 270.8m) |
| Beneish M-Score: 3.29 (Cap -4..+1) = D |
What is the price of MGNX shares?
Over the past week, the price has changed by +3.43%, over one month by +1.12%, over three months by +26.57% and over the past year by -28.74%.
Is MGNX a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.4 | 87.8% |
| Analysts Target Price | 3.4 | 87.8% |
| ValueRay Target Price | 1.6 | -11% |
MGNX Fundamental Data Overview February 03, 2026
P/B = 1.8222
P/EG = 0.01
Revenue TTM = 126.0m USD
EBIT TTM = -70.6m USD
EBITDA TTM = -63.1m USD
Long Term Debt = 37.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.14m USD (from shortTermDebt, last quarter)
Debt = 37.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.1m USD (from netDebt column, last quarter)
Enterprise Value = 6.38m USD (115.8m + Debt 37.0m - CCE 146.4m)
Interest Coverage Ratio = -16.58 (Ebit TTM -70.6m / Interest Expense TTM 4.26m)
EV/FCF = -0.04x (Enterprise Value 6.38m / FCF TTM -164.8m)
FCF Yield = -2584 % (FCF TTM -164.8m / Enterprise Value 6.38m)
FCF Margin = -130.8% (FCF TTM -164.8m / Revenue TTM 126.0m)
Net Margin = -60.23% (Net Income TTM -75.9m / Revenue TTM 126.0m)
Gross Margin = 73.67% ((Revenue TTM 126.0m - Cost of Revenue TTM 33.2m) / Revenue TTM)
Gross Margin QoQ = 81.63% (prev 59.96%)
Tobins Q-Ratio = 0.02 (Enterprise Value 6.38m / Total Assets 270.8m)
Interest Expense / Debt = 9.03% (Interest Expense 3.34m / Debt 37.0m)
Taxrate = 0.0% (0.0 / 16.8m)
NOPAT = -70.6m (EBIT -70.6m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 5.22 (Total Current Assets 232.1m / Total Current Liabilities 44.5m)
Debt / Equity = 0.55 (Debt 37.0m / totalStockholderEquity, last quarter 67.0m)
Debt / EBITDA = 0.68 (negative EBITDA) (Net Debt -43.1m / EBITDA -63.1m)
Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -43.1m / FCF TTM -164.8m)
Total Stockholder Equity = 77.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.36% (Net Income -75.9m / Total Assets 270.8m)
RoE = -98.30% (Net Income TTM -75.9m / Total Stockholder Equity 77.2m)
RoCE = -61.84% (EBIT -70.6m / Capital Employed (Equity 77.2m + L.T.Debt 37.0m))
RoIC = -91.49% (negative operating profit) (NOPAT -70.6m / Invested Capital 77.2m)
WACC = 11.23% (E(115.8m)/V(152.8m) * Re(11.93%) + D(37.0m)/V(152.8m) * Rd(9.03%) * (1-Tc(0.0)))
Discount Rate = 11.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.09%
Fair Price DCF = unknown (Cash Flow -164.8m)
EPS Correlation: 26.76 | EPS CAGR: 114.1% | SUE: 0.58 | # QB: 0
Revenue Correlation: 12.97 | Revenue CAGR: 54.81% | SUE: 2.07 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.66 | Chg30d=+0.025 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.72 | Chg30d=+1.063 | Revisions Net=+0 | Growth EPS=-94.0% | Growth Revenue=-35.2%